Showing 1 - 14 results of 14 for search 'Peter NASH', query time: 0.03s
Refine Results
-
1
Symposium 8 <subtitle>Role of IL-23 Inhibitors in PsA Management — Can It Be Considered Upfront?</subtitle> by Peter NASH
Published 2023-11-01
Article -
2
Long-Term Durability of Certolizumab Pegol in Patients with Rheumatoid Arthritis Over 5 Years: An Analysis of Pooled Clinical Trial Data by Vivian P. Bykerk, Peter Nash, David Nicholls, Yoshiya Tanaka, Kevin Winthrop, Christina Popova, Nicola Tilt, Derek Haaland
Published 2023-02-01
Article -
3
The effect of ixekizumab on axial manifestations in patients with psoriatic arthritis from two phase III clinical trials: SPIRIT-P1 and SPIRIT-P2 by Atul Deodhar, Dafna Gladman, Rebecca Bolce, David Sandoval, So Young Park, Soyi Liu Leage, Peter Nash, Denis Poddubnyy
Published 2023-08-01
Article -
4
-
5
Comparative effectiveness of secukinumab and etanercept in biologic-naïve patients with psoriatic arthritis assessed by matching-adjusted indirect comparison by Philip Mease, Ernest Choy, Peter Nash, Chrysostomos Kalyvas, Matthias Hunger, Luminita Pricop, Kunal K. Gandhi, Steffen M. Jugl, Howard Thom
Published 2019-07-01
Article -
6
P163 Efficacy of deucravacitinib, a first-in-class, oral, selective, allosteric tyrosine kinase 2 inhibitor, in musculoskeletal manifestations of systemic lupus erythematosus: a su... by Richard Furie, Peter Nash, Amit Saxena, Thomas Dörner, Subhashis Banerjee, Joan Merrill, Marilyn Pike, Coburn Hobar, Samantha Pomponi, Ravi Koti, Thomas Wegman
Published 2024-03-01Article -
7
Guselkumab provides durable improvement across psoriatic arthritis disease domains: post hoc analysis of a phase 3, randomised, double-blind, placebo-controlled study by Laure Gossec, Peter Nash, Philip J Mease, Emmanouil Rampakakis, Laura C Coates, Philip S Helliwell, Alexa P Kollmeier, Xie L Xu, May Shawi, Miriam Zimmermann, Natalie J Shiff
Published 2024-03-01
Article -
8
A Comprehensive Review of Ixekizumab Efficacy in Nail Psoriasis from Clinical Trials for Moderate-to-Severe Psoriasis and Psoriatic Arthritis by Bruce W. Kirkham, Alexander Egeberg, Frank Behrens, Andreas Pinter, Joseph F. Merola, Thorsten Holzkämper, Gaia Gallo, Khai Jing Ng, Rebecca Bolce, Christopher Schuster, Peter Nash, Luis Puig
Published 2023-07-01
Article -
9
Impact of filgotinib on pain control in the phase 3 FINCH studies by Bruno Fautrel, Peter Nash, Arthur Kavanaugh, Peter C Taylor, René Westhovens, Rieke Alten, Janet Pope, Dick de Vries, Chris Watson, Georg Pongratz, Pieter-Jan Stiers, Ken Hasegawa, Shangbang Rao
Published 2024-02-01
Article -
10
MACE and VTE across upadacitinib clinical trial programmes in rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis by Peter Nash, Iain B McInnes, Ernest Choy, Jeffrey R Curtis, Eduardo Mysler, Christina Charles-Schoeman, Nasser Khan, Kunihiro Yamaoka, Ralph Lippe, Hannah Palac, Anna K Shmagel, Jessica Suboticki
Published 2023-10-01
Article -
11
Long-term safety of tofacitinib up to 9.5 years: a comprehensive integrated analysis of the rheumatoid arthritis clinical development programme by Peter Nash, Yoshiya Tanaka, Kevin L Winthrop, Eun Bong Lee, Xavier Mariette, Jeffrey R Curtis, Kenneth Kwok, Connie Chen, Pinaki Biswas, Lisy Wang, Christina Charles-Schoeman, Ann Madsen, Stanley B Cohen, Andrea Shapiro, Jürgen Wollenhaupt
Published 2020-10-01
Article -
12
Safety profile of upadacitinib over 15 000 patient-years across rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis and atopic dermatitis by Peter Nash, Atul Deodhar, Philip J Mease, Yoshiya Tanaka, Tim Shaw, Gerd R Burmester, Kevin L Winthrop, Alan D Irvine, Eduardo Mysler, Stanley B Cohen, Ana P Lacerda, John Liu, Hannah Palac, Emma Guttman‑Yassky
Published 2023-02-01
Article -
13
Correction: Efficacy and Safety of Filgotinib in Patients with High Risk of Poor Prognosis Who Showed Inadequate Response to MTX: A Post Hoc Analysis of the FINCH 1 Study by Bernard G. Combe, Yoshiya Tanaka, Maya H. Buch, Peter Nash, Gerd R. Burmester, Alan J. Kivitz, Beatrix Bartok, Alena Pechonkina, Katrina Xia, Kahaku Emoto, Shungo Kano, Thijs K. Hendrikx, Robert B. M. Landewé, Daniel Aletaha
Published 2023-01-01
Article -
14
Efficacy and Safety of Filgotinib in Patients with High Risk of Poor Prognosis Who Showed Inadequate Response to MTX: A Post Hoc Analysis of the FINCH 1 Study by Bernard G. Combe, Yoshiya Tanaka, Maya H. Buch, Peter Nash, Gerd R. Burmester, Alan J. Kivitz, Beatrix Bartok, Alena Pechonkina, Katrina Xia, Kahaku Emoto, Shungo Kano, Thijs K. Hendrikx, Robert B. M. Landewé, Daniel Aletaha
Published 2022-10-01
Article